Union Home Minister Amit Shah laid the foundation stone for India's first state-funded Biosafety Level-4 (BSL-4) laboratory on January 13, 2026, at the Gujarat Biotechnology Research Centre (GBRC) in Gandhinagar. The facility, to be built at a projected cost of ₹362 crore across 11,000 square metres, will be a multi-tier structure incorporating BSL-4, BSL-3, and BSL-2 modules alongside ABSL-3 and ABSL-4 (Animal Biosafety Level) modules for studying viral interactions with living organisms. BSL-4 laboratories are the highest-containment research facilities, reserved for studying dangerous pathogens with no known vaccine or treatment that are transmissible via aerosols — such as Ebola, Marburg, and Nipah viruses. While India has centrally-funded high-containment facilities like the National Institute of Virology (NIV) in Pune, the Gujarat facility marks the first time a state government is financing and managing such infrastructure. Planning for this facility began in mid-2022, driven by lessons from the COVID-19 pandemic regarding the need for local diagnostic and research capability to detect and respond to emerging infectious diseases rapidly. The facility aligns with India's 'One Health' framework, which recognises the interconnected nature of human, animal, and environmental health. The Biosafety Level classifications range from BSL-1 (handling low-risk agents) to BSL-4 (handling the most dangerous exotic agents), with BSL-3 facilities handling agents like Mycobacterium tuberculosis and SARS-CoV-2.